Evolving synergistic combinations of targeted immunotherapies to combat cancer

被引：590

作者：

Melero, Ignacio ^{[1
,2
]}

Berman, David M. ^{[3
]}

Angela Aznar, M. ^{[1
,2
]}

Korman, Alan J. ^{[4
]}

Perez Gracia, Jose Luis ^{[1
,2
]}

Haanen, John ^{[5
]}

机构：

[1] Univ Navarra, CIMA, E-31008 Pamplona, Spain

[2] Univ Navarra, Clin Univ, E-31008 Pamplona, Spain

[3] Bristol Myers Squibb Co, Lawrenceville, NJ 08648 USA

[4] Bristol Myers Squibb Co, Biol Discovery Calif, Redwood City, CA 94063 USA

[5] Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands

来源：

NATURE REVIEWS CANCER | 2015年 / 15卷 / 08期

关键词：

IMMUNOSTIMULATORY MONOCLONAL-ANTIBODIES; TUMOR-INFILTRATING LYMPHOCYTES; CD8(+) T-CELLS; FC-GAMMA-RIIB; ANTI-GITR MAB; REGULATORY T; CTLA-4; BLOCKADE; CLINICAL ACTIVITY; IMMUNE-RESPONSES; PROSTATE-CANCER;

D O I：

10.1038/nrc3973

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Immunotherapy has now been clinically validated as an effective treatment for many cancers. There is tremendous potential for synergistic combinations of immunotherapy agents and for combining immunotherapy agents with conventional cancer treatments. Clinical trials combining blockade of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) may serve as a paradigm to guide future approaches to immuno-oncology combination therapy. In this Review, we discuss progress in the synergistic design of immune-targeting combination therapies and highlight the challenges involved in tailoring such strategies to provide maximal benefit to patients.

引用

页码：457 / 472

页数：16

共 183 条

[1]

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 [J].